The purpose of this study was to determine the frequency with which magnetic resonance (MR) imaging detects avascular necrosis of the bone (AVNB) in children with acute lymphoblastic leukemia (ALL) or advanced-stage non-Hodgkin lymphoma (NHL) who receive prednisone during remission induction, reinduction, and maintenance chemotherapy; to assess the clinical significance of these findings; and to identify factors predictive of AVNB. We prospectively obtained MR imaging of the hips and knees of 116 children who had completed at least 1 year of treatment for ALL or advanced-stage NHL on identical prednisone-containing regimens between December 1991 and October 1994. MR imaging findings of AVNB were compared with clinical outcomes, and the effect of therapeutic and patient factors on the frequency of AVNB was analyzed. The MR imaging findings of 17 of the 116 participating patients were consistent with AVNB. The most common clinical manifestation was joint pain (11 patients). Only one patient had progressive joint deterioration that necessitated surgical replacement. Only age 10 years or more at the time of the primary diagnosis was significantly associated with the development of AVNB (P = 0.004). MR imaging showed changes consistent with AVNB in approximately 15% of this patient population. However, most patients in this study who had MR imaging signs of AVNB did not experience progressive joint destruction, even with continued prednisone therapy. Therefore, the clinical usefulness of MR imaging as a screening tool for AVNB in this set of patients remains uncertain. Leukemia (2001) 15, 891-897.
Introduction
Avascular necrosis of bone (AVNB) is a recognized complication of treatment for leukemia and lymphoma. [1] [2] [3] [4] [5] Its reported frequency varies from 0% to 40%, depending on the type of therapy administered and the imaging methods employed to detect AVNB. 4, [6] [7] [8] [9] Although the etiology of AVNB is not well understood, there is some evidence suggesting that AVNB results from ischemic insult to the bone and bone marrow. [10] [11] [12] [13] The subsequent death of a segment of bone leads to progressive joint damage.
The type and dose intensity of corticosteroid therapy used to treat leukemia and lymphoma appear to be important factors in the development of symptomatic AVNB. Between 1971 and 1984 , when the use of glucocorticoids was largely restricted to the first 4 weeks of remission induction therapy, no symptomatic AVNB was noted among 1217 patients treated for leukemia at St. Jude Children's Research Hospital. After the addition of prednisone to the continuation chemotherapy regimen, AVNB was detected in 1.4% of patients. 6 The frequency of AVNB appears to be greater when dexamethasone is administered, 4, 5, 14, 15 although this finding may reflect the greater dose intensity with which dexamethasone is usually given for acute lymphoblastic leukemia (ALL). The dose intensity of methotrexate or l-asparaginase given with glucocorticoids may also be factors in the development of AVNB. 16, 17 Individual susceptibility plays a role as well; some patients have experienced AVNB after receiving corticosteroids at a relatively low dose intensity. 18, 19 The presenting symptoms of AVNB are usually progressive leg pain, articular pain, or both. Plain radiographs are usually uninformative in the early stages of AVNB. 4 Magnetic resonance (MR) imaging can reveal the development of AVNB before it becomes evident on plain radiographs or even before the emergence of characteristic clinical manifestations. 20 Thus, MR imaging may provide a useful screening tool for AVNB in children undergoing intensive chemotherapy for leukemia or lymphoma. 4, 21 To investigate the usefulness of MR imaging screening for AVNB in this patient population, we prospectively performed MR imaging of the hips and knees of 116 children treated for ALL or advanced-stage non-Hodgkin lymphoma (NHL) with an intensive regimen that included a cumulative prednisone dose of approximately 10 g/m 2 . We assessed the frequency of AVNB as detected by MR imaging, the outcomes of patients found to have AVNB by this method, and the effect of continued prednisone therapy, cumulative doses of steroids and methotrexate, and individual patient factors on the frequency of these findings.
Materials and methods

Patients
Between December 1991 and August 1994, 176 children and adolescents 18 years of age or younger with newly diagnosed ALL (167 patients) or advanced-stage NHL (nine patients) were enrolled on the Total Therapy XIIIA 22 and NHL XIII protocols at St Jude Children's Research Hospital. The diagnosis of ALL was based on morphologic and cytochemical evaluation of bone marrow smears and on immunophenotypic and cytogenetic analysis of lymphoid blast cells. ALL blast cells were classified as T cells or B cell precursors on the basis of reactivity to a panel of monoclonal antibodies, as previously described. 23 Leukemic involvement of the central nervous system was assessed as detailed elsewhere. 22 Patients enrolled on the Total XIIIA and NHLXIII protocols were contacted by telephone or letter and invited to participate in this study. Twenty-eight did not respond, 20 died before the study opened, seven declined to participate, four did not appear for their MR imaging appointments, and one discontinued treatment at St Jude. A total of 116 patients (107 with ALL and nine with NHL) participated in the study. There were no significant differences in the distribution of clinical and biological features between patients with ALL who did and who did not participate in the study (age Ͻ10 vs у10 years, P = 0.45; male vs female, P = 0.41; white vs others, P = 0.8; white blood cell count р50 × 10 9 /l vs Ͼ50 × 10 9 /l, P = 0.84; B-lineage vs T-lineage ALL, P = 0.612).
Imaging evaluation
Participating patients underwent T1-weighted and short tau inversion recovery (STIR) MR imaging of the hips and knees after completing at least 1 year of therapy. If positive findings were noted in the coronal images, transverse T2-weighted images of the hips, knees, or both were obtained. The MR findings were considered to be consistent with AVNB if the T1, T2, or STIR images showed one or more focal signal abnormalities (sharply defined lesions with low-intensity margins on any combination of the sequences, with or without an inner ring of high intensity on T2-weighted or STIR images) of any size in the femoral head, condyles, or both (Figures 1  and 2) . 24 When MR imaging findings were consistent with AVNB, plain radiographs of the affected joints were obtained. Radiographic abnormalities, if present, were staged according to the methods of Ficat and Arlet 25, 26 by a radiologist (BDF) who was blinded to clinical details.
Patients who had completed treatment for ALL or NHL and did not have AVNB underwent MR imaging only once. Patients who were still undergoing treatment for ALL or NHL had imaging studies every 6 months. Patients whose imaging studies showed changes consistent with AVNB had follow-up MR imaging or plain radiographic studies every 6 months until the lesions improved or stabilized. At the time this study was designed, 90% of the patients enrolled on the Total Therapy XIIIA and NHL XIII protocols had completed their scheduled chemotherapy; thus, only a small number of patients who did not show evidence of AVNB had imaging studies in addition to those required by the therapy protocols. Patients who had had MR imaging evidence of AVNB before this study began were eligible to participate; they received an MR imaging examination every 6 months for follow-up. Patients who were receiving salvage therapy after relapse were also eligible for the study. The St Jude Children's Research Hospital Institutional Review Board approved this protocol, and informed consent was obtained from the patients, parents, or guardians, as appropriate.
Treatment plan
All patients received methotrexate in the 'up-front window' before remission induction therapy began. Patients with ALL were randomly assigned to receive either high-dose methotrexate ( . Reinduction therapy (similar to induction therapy described above) was administered from weeks 32 to 37. l-asparaginase was discontinued after week 37.
Postremission treatment for patients with lower-risk disease ) every 4 weeks. Central nervous system therapy was given as previously described. 22 Because of the high rate of hospitalization for fever and neutropenia among the first 26 patients enrolled, two doses of etoposide plus cytarabine were subsequently eliminated from the reinduction regimen and l-asparaginase was eliminated from continuation therapy.
Patients who experienced relapsed ALL were retreated on the St Jude relapse study (R-15 protocol). They were randomly assigned to receive oral etoposide 50 mg/m 2 
Statistical analysis
The methods of Clopper and Pearson 27 were used to calculate a 95% confidence interval for the proportion of patients who had AVNB that was detected by MR imaging. Logistic regression analyses were used to determine whether prospectively defined factors were useful in predicting a patient's risk of AVNB. The effect of body mass index (BMI) on the risk of AVNB was assessed by using national reference data 28 to calculate a z-score for each patient's BMI to adjust for sex and for age at the time of diagnosis. Patients less than 2 years of age, for whom BMI is not defined, were excluded from this analysis.
Fifty-seven patients received other steroids in lieu of or in addition to prednisone because of medical problems or relapsed leukemia. The cumulative doses of these steroids were converted to the equivalent prednisone doses for purposes of calculating the cumulative steroid dose. The following conversion factors, which are based on the anti-inflammatory potency of the steroids, were used: prednisolone (× 1.0), dexamethasone (× 5. 
Results
Seventeen of the 116 participating children (15.5%) had MR imaging evidence of AVNB (Figures 1 and 2) . The clinical characteristics of these patients and the Ficat staging of the involved joints are shown in Tables 1 and 2 . The knees were the joints most often affected (14 of 16 patients). The hips of nine of 16 patients tested were affected, and six patients had involvement of both the hips and the knees. The median age of the 10 male and seven female patients at diagnosis of ALL/NHL was 11.5 years. Fifteen patients had ALL and two had NHL. The median time between the primary diagnosis and the detection of AVNB was 3 years (range, 1 to 5.6 years). Joint pain, the most common symptom, occurred in 11 Eight patients had completed all planned therapy when AVNB was diagnosed, and nine were receiving antileukemic treatment: seven of the nine were receiving treatment on the Total XIIIA protocol, and two (patients 2 and 10) were receiving salvage therapy containing dexamethasone after completing Total XIIIA therapy and subsequently experiencing relapse. All of the seven patients who were being treated on the Total XIIIA protocol had joint pain; six continued to receive prednisone after MR imaging changes were detected.
We obtained plain radiographs of 30 joints (hips and knees) that showed MR imaging evidence of AVNB; 18 (53%) of these showed plain radiographic abnormalities. Eight patients underwent repeated MR imaging of the affected joints 1 year after the initial diagnosis of AVNB. MR imaging abnormalities had not changed for seven of the eight patients; one patient's abnormal findings had resolved.
Fifteen of the 17 patients with AVNB were alive at the time of this report; two had died of relapsed leukemia. Fourteen of the 15 had survived free of disease for 5 or more years after the primary diagnosis. Only one patient had required hip replacement. He continues to have bilateral hip pain requiring daily treatment with nonsteroidal anti-inflammatory drugs. Of the remaining 14 patients, one had hip and knee pain that was not debilitating, five had occasional or mild joint pain associated with exercise, and eight were free of symptoms ( Table 3) .
As shown in Table 4 , we examined the association between the frequency of AVNB and age, white blood cell count, body mass index, sex, cumulative doses of methotrexate and corticosteroids, and treatment with dexamethasone. Only age у10 years at the time of the primary diagnosis was highly associated with AVNB (P = 0.004).
Discussion
In this study, approximately 15% of the 116 children receiving prednisone during the induction, intensification, and maintenance phases of therapy for ALL or advanced-stage NHL showed MR imaging evidence of AVNB. Although no comparable study has been reported, this finding is likely to reflect the actual frequency of AVNB in this population; 90% of the patients had completed therapy at the time they were enrolled on the study, and the remaining 10% had MR imaging every 6 months until they completed therapy. In adults who received prolonged prednisolone therapy for autoimmune disorders or for kidney transplantation, the frequency of MR imaging changes in the femoral head was more than twice that observed in our study. 21, 29 Although it is difficult to estimate the cumulative doses of prednisone administered in these studies, the average cumulative dose given during the first year in one study (10.3 g/m 2 ) 21 was twice the cumulative dose received by our study patients during the same time period. It is unknown whether this large cumulative dose explains the much higher rates of AVNB in adults or whether these findings also reflect the apparently greater frequency of AVNB with increasing age, the type of primary disease, pharmacokinetic differences in steroid metabolism, the schedule of corticosteroid administration, or other constitutional factors.
Factors that may predispose children with ALL to AVNB are largely unknown. There has been an effort to identify surrogate markers that can predict the risk of AVNB and its complications. In the present study, only age Ͼ10 years was associated with an increased risk of AVNB. This finding is consistent with other reports that the frequency of AVNB is directly related to age in patients being treated for leukemia. 5 Body mass index, white blood cell count, sex, and cumulative dose of methotrexate were not found to be significantly associated with AVNB.
Although a small number of our patients with AVNB had received additional doses of prednisone or corticosteroids other than prednisone to manage medical problems, including relapsed ALL, we found no relationship between the cumulative dose of corticosteroids and the risk of AVNB. Two study patients who developed severe AVNB had received only half the planned cumulative dose of prednisone at the time AVNB Patients 2 and 9 were receiving salvage therapy at the time AVNB was diagnosed. b Patient 9 had a diagnosis of AVNB before relapse of ALL. was detected. This observation is corroborated by several reports showing no significant correlation between the occurrence of AVNB and the cumulative prednisone-equivalent dose of corticosteroids. 5, 19, 30 It is possible that the cumulative dose of corticosteroids is related to the incidence of AVNB in a subset of patients, such as those above the age of 10 years.
The type of corticosteroid administered may affect the risk of AVNB. In a study by Ojala et al, 4 children with newly diagnosed ALL had MR imaging before and at several time points during therapy; nine of 21 patients (42%) who received dexamethasone during intensification therapy showed MR imaging evidence of AVNB, usually after dexamethasone was administered. On the basis of the efficacy-equivalence ratio Leukemia of 1:5.5 (1 mg/m 2 dexamethasone = 5.5 mg/m 2 prednisone) used in that study, the cumulative dose of corticosteroid was actually lower than that given in our study. Thus, dexamethasone may be more likely than prednisone to cause the abnormalities detected by MR imaging. Additional studies are needed to confirm this hypothesis.
Only one patient of the 14 in our study who had MR imaging findings of AVNB and who were long-term disease-free survivors had progressive joint disease that required total hip replacement. The morbidity of the remaining 13 patients has been mild. Although some continue to experience pain, mostly associated with intense physical exercise, none has experienced progressive disease requiring joint replacement. Some investigators have proposed that MR imaging be used to screen patients with ALL for early signs of AVNB and that corticosteroid therapy be discontinued when findings are positive. This proposal was based on the premise that AVNB has become advanced by the time clinical or plain radiographic manifestations appear and that progressive joint destruction is inevitable. 31 Although MR imaging is very sensitive in detecting AVNB, the clinical implications of these findings remain unknown. Even when these findings occur in conjunction with joint pain or plain radiographic changes, the patient's clinical course is unpredictable. Of the 10 study patients who had not only MR imaging evidence of AVNB but also clinical manifestations, plain radiographic evidence, or both and who continued to receive prednisone, only one experienced progressive, debilitating joint disease. None of the nine children described by Ojala et al 4 as having MR imaging changes consistent with AVNB had required any treatment as of March 2000 (AE Ojala, personal communication). In another MR imaging study of adult patients receiving prednisolone for autoimmune disorders, the size of femoral lesions underwent spontaneous reduction in 14 of 32 affected hip joints (45%). 21 Taken together, the available information suggests that MR imaging evidence of AVNB should be interpreted with caution. Other features, such as the patient's age, type of joints involved, intensity and time of appearance of symptoms, and type of steroid used should be considered before antileukemic treatment is modified. It is unlikely that MR imaging screening will benefit patients whose ALL therapy includes only prednisone at cumulative doses equal to or less than those used in this study. However, MR imaging monitoring may benefit patients who receive dexamethasone therapy. A recent study by the CCG group showed substantial morbidity among 104 patients with ALL who received prolonged courses of steroids, including dexamethasone, and who experienced symptomatic AVNB: 46 of these patients had severely limited activity and nearly half of them required narcotic analgesia. 32 Although some patients may benefit from discontinuation of corticosteroid therapy if progressive AVNB is anticipated, there is no reliable means of identifying which patients are at risk of debilitating progressive joint disease. Korholz et al 14 have suggested that the size (Ͼ900 mm 2 ) and location (cartilaginous surface) of the lesion are associated with the risk of progression. However, individual susceptibility to corticosteroids may also play a role in the frequency and rate of progression. In the case of susceptible patients, discontinuation of corticosteroids may prevent subsequent joint destruction. The single patient in our study (patient 12) whose prednisone therapy was discontinued after 1 year of treatment because of severe joint pain and plain radiographic evidence of AVNB (Ficat stage 3; cumulative prednisone dose, 6.1 g/m 2 ) remains clinically well and experiences only occasional mild hip pain, 7 years after the diagnosis of ALL.
Musculoskeletal pain is relatively common during treatment of leukemia. In the early phases of treatment, pain is likely to be related to disease, infection, or medications. During maintenance therapy, pain in the extremities and joints is more common during the weeks when the vincristine-steroid combination is given. These symptoms are often attributed to neuropathic pain caused by vincristine. Although MR imaging has shown AVNB in some of these patients, MR imaging evidence of AVNB may also be present in the absence of pain. Therefore, the relationship between pain and AVNB in this set of patients remains unclear.
In conclusion, approximately 15% of children with ALL or advanced-stage NHL whose therapy includes large cumulative doses of prednisone have MR imaging changes consistent with AVNB after the first year of therapy. Almost all of these patients can complete their prescribed therapy without experi-encing significant joint damage. Patients who experience joint pain and who have abnormal MR imaging changes early in the course of treatment may be at higher risk of joint destruction and may benefit from discontinuation of prednisone.
